"Fluorobenzenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of BENZENE that contain FLUORINE.
Descriptor ID |
D005464
|
MeSH Number(s) |
D02.455.426.559.389.358 D02.455.526.510.432
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluorobenzenes".
Below are MeSH descriptors whose meaning is more specific than "Fluorobenzenes".
This graph shows the total number of publications written about "Fluorobenzenes" by people in this website by year, and whether "Fluorobenzenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2002 | 3 | 0 | 3 |
2003 | 3 | 0 | 3 |
2004 | 2 | 0 | 2 |
2005 | 0 | 2 | 2 |
2006 | 1 | 0 | 1 |
2007 | 5 | 0 | 5 |
2008 | 2 | 1 | 3 |
2009 | 1 | 1 | 2 |
2010 | 0 | 1 | 1 |
2011 | 3 | 0 | 3 |
2012 | 4 | 0 | 4 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorobenzenes" by people in Profiles.
-
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
-
What is the nature of serotonergic abnormalities in human aggression? Biol Psychiatry. 2012 Dec 15; 72(12):980-1.
-
The effect of rosuvastatin in a murine model of influenza A infection. PLoS One. 2012; 7(4):e35788.
-
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
-
Lipoprotein-associated phospholipase A2 measurements: mass, activity, but little productivity. Clin Chem. 2012 May; 58(5):814-7.
-
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
-
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis. 2012 Apr; 221(2):471-7.
-
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
-
The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.